Tag Archives: Pfizer

Are pharmaceutical mega-mergers in the public interest?

The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development –  R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading

Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: The Pharmaceutical Industry – Friend or Foe?

Recent months have seen publicity over examples of disgraceful behaviour by pharmaceutical companies. The question arises as to whether the failings have been rare and exceptional or whether they are indicative of generally low moral standards in the industry. Pharmaceutical … Continue reading

Posted in Alcohol, Business, Drugs, Finance, GPs, Information, NHS, Obesity, Research | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Political Mood Change over the NHS, Innovation and the Pharmaceutical Industry in 2011

As 2011 draws to a close now is a good time to reflect on the period since the last UK General Election in 2010. We must consider what we have done right, what we have done wrong and what remains … Continue reading

Posted in Business, David Cameron, Department of Health, Drugs, Election, Genetics, Health Bill, Health Team, Hospitals, Innovation, NHS, Pharma, Policy, Research | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Pills, pricing and growth

Warfarin, toxin of choice to rid us of nasty rats, is also the drug of choice to stop you having a blood clot. Liberally prescribed on the NHS, the tablets cost peanuts. However it’s not perfect. You can’t take it … Continue reading

Posted in Business, Drugs, Innovation, Uncategorized | Tagged , , , , , , | Leave a comment

Guest Blogspot – The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines

The UK Government yesterday published its detailed response to the three-month public consultation concluded in March 2011 on value-based pharmaceutical pricing. The Government has emphasised that work on the proposals is still at an early stage. The mistake made with … Continue reading

Posted in Andrew Lansley, Business, Department of Health, Drugs, Employment, Finance, Innovation, NHS, Patients, Pharma, Policy, Research | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspote: How to encourage pharmaceutical R&D

Politicians should only attempt the possible. We must recognise what we cannot do. The UK Government alone cannot influence the direction of R&D significantly. The sums of money involved are so vast that R&D only makes sense in a global … Continue reading

Posted in Andrew Lansley, Business, competition, Department of Health, Drugs, Health Bill, Hospitals, Innovation, NHS, Pharma, Policy, Research, Uncategorized, White Paper | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Pfizer closure a blow to science and growth confidence

Whilst Pfizer are saying that their closure of their Kent-based research site is due to internal changes in priorities it highlights both fundamental changes in the approach to drug research and development (R&D) and the urgent need for the UK … Continue reading

Posted in Drugs, Pharma | Tagged , , , , , | Leave a comment